Biochip "encounter" blitz
Release date: 2006-10-25 Biochip "Encounter" is popular in China. Biochip companies are entering the ranks of international leaders. More than 500 kinds of biochips and related products have been released, mainly for autoimmune disease detection, pathogenic microorganism detection, food safety testing, hla points. Type test (bone marrow matching), health screening. Polypropylene is a thermoplastic polymer used in a wide range of applications among which we usually use it to make pharmaceutical packaging products. Each time when we receive the original Polypropylene materials we have ordered, we will do a series of modifications on them to form some useful pellets that will used in our products. One kind of these reproduced particles will be used to make caps for pharmaceutical ampoule bottles. We now have a big stable customer base in our domestic market. In future, we will do our best to serve the worldwide clients. If you are looking for a cooperator in our country, maybe we are a good choice for you. Warmly wait for your inquires! Pp Resin For Plastic Ampoule,Resin For Bottle,Modified Polypropylene Granules,Medical Ampoule Bottle SUZHOU CRH PHARMACEUTICAL TECHNOLOGY CO.,LTD , https://www.crh-health.com
In the next five years, the prospects for biochips in clinical testing, biosafety testing, import and export quarantine testing, forensic identification, and health screening will be better and better. By 2010, the global biochip market will reach $4.2 billion.
The "2006 International Bio-Nano-Information Fusion Conference and International Biochip Technology Forum" was closed in Beijing on October 12. The latest information from the meeting showed that -
International average annual growth of 14.1%
Biochip technology is a high-tech that has developed rapidly in the life sciences since the 1990s. It is a reduced biochemical analyzer that combines micro-structures and biochemical processing on microchips to integrate thousands of life-related information on a 1 cm square chip to achieve cell Accurate, fast, and informative detection of proteins, DNA, and other biological components. At present, the application of biochips covers all fields of biotechnology such as biology, medicine, pharmacy, agronomy, environmental protection, forensics, and hygiene.
The world drug market involved in pharmacological genetics and pharmacogenomics research with biochips is about $180 billion a year. According to statistics, the global biochip production value in 2005 was about 2.3 billion US dollars. Among them, the US market output value is about 1.58 billion US dollars, the Chinese market output value is about 410 million yuan, of which the output value related to health checkup is about 180 million yuan. It is estimated that by 2010, the global biochip market will reach an output value of 4.2 billion US dollars, with an average annual growth rate of about 14.1%.
At present, relevant institutions in China are conducting protein chip research, in order to produce new chips with sensitive, specific and fixed a large number of active proteins. In the 21st century, this technology will not only greatly promote the early diagnosis and monitoring of disease, but also have broad development prospects in the fields of environmental protection, food hygiene, bioengineering, and industrial pharmacy.
Multinational companies use for new drug screening In recent years, biochip technology has become a hot spot in international biotechnology research and development. Gene chips, protein chips, cell chips, tissue chips, etc. have been developed earlier, and mature microarray chips have been widely used. Microfluidic chips and other technologies are gradually maturing and are being applied in various fields.
Due to the huge commercial value and application prospects of biochip technology, developed countries such as the United States and Britain are increasing their investment in related research.
The United States has long dominated the global biochip research and development. On December 27, 2004, the US Food and Drug Administration issued the medical diagnostic access license to Roche Diagnostics' dna chip and the chip scanner produced by affymetix. In the detection of infectious diseases, the microarray-related gene chip jointly developed by affymetrix and the French bioMerieux company may be reported to fda in recent years.
Almost all multinational pharmaceutical companies around the world have invested heavily in the use of gene chips for ultra-high-throughput screening of new drugs and pharmacogenetics and pharmacogenomics research. Many important international multinational companies are optimistic about the market prospects of biochips and have increased their investment.
There are 356 patents in China. China is the first country in the world to approve biochips to enter the clinic, nearly three years earlier than the United States. At present, there are more than 500 kinds of biochips and related products in China. From 2002 to 2005, the cumulative sales of biochips was nearly 250 million yuan. More than 10 chips or related products were industrialized, and engineering research in Beijing and Shanghai The center has become the industry leader, and nearly 50 biochip R&D institutions and more than 30 biochip companies in Tianjin, Xi'an and Nanjing have also flourished.
The Biochip Beijing National Engineering Research Center has reached or exceeded international standards in the research of gene chips, protein chips, cell chips and microfluidic chip technologies. For example, its application of autoimmune disease detection, pathogenic microbial detection, food safety testing, hla typing (bone marrow matching), health screening and other application-type chip technologies closely related to the health of the whole population has been ahead of developed countries in the West. . It is understood that the biochip Beijing National Engineering Research Center has 5 products into the international market, including the export orders of laser confocal scanners to Europe, America, South Korea and other regions have reached 100-scale scale, realizing the original life science instruments in China. The first export marks that China's biochip companies have entered the ranks of international leaders.
Experts believe that low-density clinical test chips will become the entry point for biochips to enter the clinic. In the future, more mature biochip products can be taken from the laboratory into clinical routine testing, and clinicians can use biochip technology to achieve early diagnosis and individualized diagnosis and treatment of many diseases.
During the "10th Five-Year Plan" period, China's biochip research applied for 356 domestic patents and 62 foreign patents. The biochip research team in the major special project “Functional Genomics and Biochips†of the Ministry of Science and Technology published nearly 20 papers in international authoritative journals, and declared the genetic clusters and new genes related to infectious diseases and tumors with independent intellectual property rights. A total of 753 strains were studied for the functions of some of the genes and proteins, and a number of important results such as marker genes (cluster) for virus, bacterial infection and tumor diagnosis and targeting of sirna molecules were obtained.
Links Currently, there are three types of biochips commonly used: the first category is microarray chips, including gene chips, protein chips, cell chips, and tissue chips. The second category is microfluidic chips, including various sample preparation chips, capillary electrophoresis chips, and chromatography chips. The third category is a biochip-based integrated analysis system or chip lab. In addition, it also includes related instruments and equipment. Biochips are characterized by miniaturization, integration, parallelization, and automation.
In terms of microarray chips, China has developed hepatitis virus detection chips, respiratory pathogenic microorganism detection chips, and sexually transmitted disease pathogen detection chips. In addition, genetic disease diagnostic chips, tumor evaluation chips, and cardiovascular disease diagnostic chips are also under development. Some of the products that organize microarray chips have begun to serve medical research.
In terms of microfluidic chips, Zhejiang University, Nanjing University and other units have been actively researching and developing, especially in the capillary electrophoresis chip. In terms of biochip-related instruments, there are few domestic R&D units, and most of them rely on imports. Shanghai Medical Devices